TransMedics Group Inc
Fechado
SetorSaúde
73.67 -2.19
Visão Geral
Variação de preço das ações
24h
Mín
72.59
Máximo
75.5
Rendimento | -98M 7.3M |
|---|---|
Vendas | 13M 174M |
P/E Médio do Setor | 17.279 49.712 |
EPS | 0.3 |
Margem de lucro | 4.206 |
Funcionários | 898 |
EBITDA | -4.9M 28M |
Recomendações | Comprar |
|---|---|
Previsão para 12 meses | +59.25% upside |
Próximos Ganhos | 29 de jul. de 2026 |
|---|
Capitalização de Mercado | -744M 2.6B |
|---|---|
Abertura anterior | 75.86 |
Fecho anterior | 73.67 |
Sentimento de Notícias
By Acuity
50%
50%
128 / 342 Ranking em Healthcare
TransMedics Group Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.